Roche's pRED taps Vanderbilt cancer director as new oncology chief

Chutes and Ladders

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here at the end of each week.

Roche's pRED taps Vanderbilt cancer director as new oncology chief

Roche Pharma Research and Early Development (pRED) has tapped Dr. William Pao, a professor of medicine and head of the hematology-oncology division at Vanderbilt University Medical Center, as global head of its oncology disease and translational area. Pao will head up Roche's ($RHHBY) discovery, translational medicine and early development of innovative oncology medicines beginning May 1. Release

Roche
Dr. William Pao will lead the Oncology Disease and Translational Area at Roche Pharma Research and Early Development.


Synta
President and CEO Safi Bahcall has resigned.


Biotech

> Safi Bahcall has resigned as president and CEO of Synta Pharmaceuticals ($SNTA) and has stepped down from its board of directors. He has been replaced by a newly formed executive committee of the board. Release | More

> Aquavit Pharmaceuticals has appointed Dr. David Goldberg as chief medical officer. Release

> Moderna Therapeutics has hired Dr. Lorence Kim as chief financial officer effective April 21. Release

> Medican Enterprises ($MDCN) has appointed Wayne Hansen to the position of chief financial officer. Release

> Connect, out of San Diego, named Greg McKee its new CEO after former CEO Duane Roth died in August from a biking accident. Story

> Heat Biologics ($HTBX) appointed Dr. Taylor Schreiber as its vice president of research and development. Release

> Sorrento Therapeutics ($SRNE) brought on Mike Royal as senior vice president of clinical development. Release

> Linda Rubinstein, Piers Whitehead and Thomas Yonker joined PaxVax as, respectively, the company's chief financial officer, chief corporate development officer and vice president of project management. Release

> BioRestorative Therapies named Dr. Gregory Lutz its chief medical adviser for spine medicine. Release

> Amicus Therapeutics ($FOLD) appointed Dr. Jay Barth as its chief medical officer and promoted Bradley Campbell to chief operating officer. Release

> Canbex Therapeutics brought on Alberto Lledó as the company's chief medical officer. Release

> Andrew Hirsch, chief financial officer of Bind Therapeutics ($BIND), has been appointed as the company's chief operating officer. He will continue to serve as chief financial officer. Release

> Audentes Therapeutics has appointed Dr. Suyash Prasad as senior vice president and chief medical officer; Michael O'Callaghan as senior vice president of preclinical development and translational medicine; Barbara Wuebbels as vice president of patient advocacy and medical affairs; and Monica Miller as vice president of program and alliance management. Release

> Dr. Ada Braun has joined Biothera as chief medical officer. Release

> Prothena ($PRTA) has promoted Tara Nickerson to chief business officer. Release

Pharma

> Dr. John Weinberg, currently chief commercial officer of Veloxis Pharmaceuticals ($VELO), has been promoted to chief operating officer. Release

> Robert Carey joined Horizon Pharma ($HZNP) as the company's executive vice president and chief business officer. Release

> Vansen Pharma ($VNSN) appointed Ahmad Doroudian as its president and CEO. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.